NCT01557959View on ClinicalTrials.gov

Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions
Adenocarcinoma of the LungAdenosquamous Cell Lung CancerBronchoalveolar Cell Lung CancerLarge Cell Lung CancerNon-small Cell Lung CancerRecurrent Non-small Cell Lung CancerSquamous Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer
Interventions
DRUG

cisplatin

Given IV

BIOLOGICAL

pegfilgrastim

Given SC

DRUG

erlotinib hydrochloride

Given PO

OTHER

laboratory biomarker analysis

Optional correlative study

GENETIC

polymorphism analysis

Correlative study

OTHER

pharmacogenomic studies

Correlative study

GENETIC

genetic linkage analysis

Correlative study

DRUG

docetaxel

Given IV

Trial Locations (1)

27157

Wake Forest University Health Sciences, Winston-Salem

Sponsors

Collaborators (1)

OSI Pharmaceuticals
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

OSI Pharmaceuticals

INDUSTRY

lead

Wake Forest University Health Sciences

OTHER

NCT01557959 - Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter